Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Hesperidin

Plain-language summaryIntrigue 45 / 100

Hesperidin is a citrus flavonoid glycoside abundant in orange peel. It has antioxidant and vascular-protective effects. The glucosylated form (G-hesperidin) is much better absorbed than native hesperidin. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

Mature citrus flavonoid with real venous-indication data but negligible frontier research value

Look, hesperidin is a real compound with real clinical use. The MPFF formulation (Daflon) has legitimate phase 3 data for chronic venous insufficiency and hemorrhoids, and thats more than most supplements can claim. We dont want to dismiss that. But the question the rubric is asking is whether a bench scientist should be prioritizing this in 2025, and the honest answer is almost certainly no.

The mechanism story is what kills it. Hesperidin operates through the standard polyphenol toolkit: NF-kB pathway modulation, antioxidant activity, some inhibition of prostaglandin and leukotriene synthesis, mild influence on venous smooth muscle tone. These are not bad mechanisms. They’re just not interesting mechanisms. Every citrus flavonoid researcher has been staring at this same biology since the 1990s. Theres no novel target, no dual-action angle, nothing that makes you sit up.

The clinical attribution problem is real and underappreciated. Most of the solid human data comes from MPFF, which is a 90:10 diosmin-to-hesperidin combination. Isolating hesperidin’s contribution is methodologically messy, and the literature for hesperidin monotherapy in humans is considerably thinner. You get some small-N trials on blood pressure, some cognitive signal in older adults from a 2015 Nutrients paper, modest metabolic effects. The replication is inconsistent. We’d call this a 50 on evidence for the MPFF-supported indications, but that credit is partly borrowed.

Whats interesting, if anything, is the gut conversion angle. Hesperetin (the aglycone) is the bioavailable form, and the gut microbiome conversion rate varies dramatically between individuals. There’s genuine mechanistic work to do on why some people absorb essentially none of this and others convert efficiently. That question connects to broader microbiome-flavonoid interaction research. But that’s a story about gut biology using hesperidin as a probe, not a story about hesperidin as a therapeutic target.

Sourcing is trivial. Purity is generally fine from standard vendors. Stack interactions are minimal. None of this makes it exciting research; it makes it a compound that sits in a lot of backgrounds without causing trouble. For investigators building a library, its a low-priority inclusion. If your research program specifically concerns venous biology, flavonoid pharmacokinetics, or microbiome-mediated polyphenol conversion, it earns a spot. Otherwise, theres a long list of compounds ahead of it.

Novelty

20

Mechanism promise

22

In-category differentiation

30

Evidence quality

50

Translational signal

45

Research bench value

30

Rationale Hesperidin scores low on novelty and mechanism because it’s a decades-old polyphenol with well-understood, unremarkable flavonoid pharmacology; the MPFF/Daflon clinical record lifts evidence and translational scores somewhat, but the combination-product attribution problem limits how much credit hesperidin alone can claim, and the raw weighted score lands comfortably below any applicable cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Citrus flavonoid glycoside

A flavanone glycoside from citrus peel with vascular and anti-inflammatory effects; the principal active in Daflon.

Abstract

Hesperidin (CAS 520-26-3; molecular formula C28H34O15; molecular weight 610.57) is a flavanone glycoside present in high concentrations in citrus peel and pith. The aglycone form (hesperetin) is the bioavailable active. The compound has documented vascular effects (improved venous tone, reduced capillary fragility) and is used clinically as part of micronized purified flavonoid fraction (MPFF, Daflon) for chronic venous insufficiency and hemorrhoids. The compound is sold as a dietary supplement. Doses are typically 500 mg to 1 gram per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-188Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Escitalopram

Plain-language summaryIntrigue 65 / 100

Escitalopram (Lexapro) is the active half of citalopram pulled out and sold on its own. Lundbeck and Forest Pharmaceuticals brought it to market in 2002 after demonstrating that the inert mirror-image partner in racemic citalopram does nothing useful and may slightly hinder the active component. The mechanism is the same single-target serotonin reuptake block, just cleaner. It is the most serotonin-selective SSRI in clinical use, with very little crossover to the norepinephrine or dopamine pumps. Head-to-head trials suggest a small but real advantage in efficacy and tolerability over citalopram, which is why most prescribers now reach for it first. The dose ceiling is much lower (20 mg) because each milligram contains only the active half. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

43/100

The gold-standard SERT reference probe; clinical maturity makes it nearly invisible as a research target

Look, theres no mystery here. Escitalopram is the active enantiomer of citalopram, isolated after Lundbeck identified that the R-form was actually attenuating S-enantiomer binding through an allosteric SERT site. That allosteric story was genuinely clever pharmacology when it was described. The problem is it was described over twenty years ago, and the compound has been prescribed to hundreds of millions of people since. The research frontier, by definition, is somewhere else.

The mechanism is single-receptor SERT inhibition, and its the cleanest version of that mechanism available. Affinity around 1 nM, selectivity over NET and DAT thats the best of any clinical SSRI, half-life in the 27-32 hour range. From a bench standpoint, what that gets you is a precise SERT probe with a well-characterized pharmacokinetic profile and essentially no off-target noise to explain away. If youre running an experiment where SERT occupancy is the variable, escitalopram is arguably the reference tool of choice. Thats real bench value. We dont want to understate it.

But bench value as a reference probe is very different from being an interesting research target. The evidence base here is enormous, phase 3 over phase 3, FDA-approved for MDD and GAD, decades of real-world pharmacovigilance data. That evidence quality and translational signal drag the overall score up in the calculation but thats exactly the problem from a novelty standpoint. High evidence means low exploration potential. Everything worth knowing about SERT inhibition at this selectivity profile has been studied, published, replicated, and monetized.

What we dont see is a new angle. Theres no emerging indication with a real mechanistic rationale pushing escitalopram back into the conversation in the way that, say, ketamine reopened NMDA biology or low-dose rapamycin reopened mTOR research. The SSRI class as a whole is in a holding pattern. New work is happening in receptor-adjacent territory, psychoplastogens, sigma-1 interactions, BDNF induction kinetics, but escitalopram sits at the center of a mechanism thats fully explored rather than at the edge of something opening up.

Honestly, if your research program needs a clean SERT occupancy tool, escitalopram belongs in your toolkit. But if youre asking whether it belongs in an active research agenda as a primary object of investigation, the answer is no. The score reflects that split: high clinical evidence, clear human signal, real probe utility, very low novelty, unremarkable mechanism for 2026. A serious investigator looking at this compound today is probably validating a platform assay, not chasing a new biology.

Novelty

14

Mechanism promise

18

In-category differentiation

28

Evidence quality

87

Translational signal

78

Research bench value

58

Rationale Escitalopram scores high on evidence and translational signal because it is an approved drug with decades of replicated clinical data, but those same qualities bury it on novelty and mechanism promise; the SERT-selectivity story is interesting pharmacology from the early 2000s that is now fully characterized, leaving only its value as a reference compound to carry bench relevance.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

S-enantiomer SSRI

The (S)-enantiomer of citalopram; the active component of the racemate marketed as a separate antidepressant with improved tolerability.

Abstract

Escitalopram (S-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 128196-01-0; molecular formula C20H21FN2O; molecular weight 324.39) is the (S)-enantiomer of citalopram, marketed as Lexapro by H. Lundbeck and Forest Pharmaceuticals after FDA approval in 2002. SERT affinity is approximately 1 nM; selectivity for SERT over NET and DAT is the highest of any clinical SSRI. The active enantiomer is responsible for essentially all SERT inhibitory activity in racemic citalopram; the (R)-enantiomer attenuates (S) binding through an allosteric SERT interaction, so removing it produces a small but measurable increase in serotonergic efficacy per milligram. Plasma half-life is approximately 27 to 32 hours, slightly shorter than racemic citalopram. Hepatic metabolism via CYP2C19 with secondary CYP3A4 and CYP2D6 contribution. The compound exhibits the QTc prolongation profile of racemic citalopram but with a cleaner adverse event signature owing to the absence of the (R)-enantiomer. Approved for major depressive disorder and generalized anxiety disorder. Used as a high-purity SERT-selective reference compound in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-205Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clomipramine

Plain-language summaryIntrigue 64 / 100

Clomipramine (Anafranil) is a tricyclic antidepressant with one chlorine atom added to imipramine, a small change that flips the selectivity sharply toward serotonin. It is in fact the most potent serotonin reuptake blocker in the entire tricyclic class, with affinity rivaling modern SSRIs. The active leftover after liver metabolism then shifts steady-state activity back toward norepinephrine, so the drug ends up doing both jobs over a 24-hour period. It is the only tricyclic with FDA approval for OCD and remains a third-line option for severe OCD when SSRIs fail. The usual tricyclic burdens (sedation, anticholinergic effects, cardiac risk in overdose) all apply. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

The gold-standard TCA for OCD research but a closed mechanistic frontier with deep evidence and low novelty

Look, clomipramine is one of those compounds where the resume is genuinely impressive but the research horizon has mostly closed. Developed at Geigy in the early 1960s and FDA-approved in 1989 specifically for OCD, it’s been the clinical anchor in treatment-resistant obsessive-compulsive disorder for over three decades. The SERT Ki of roughly 0.28 nM is remarkable for a TCA. Nothing else in the class touches it. And the parent/metabolite pharmacology has a quietly interesting wrinkle: clomipramine is SERT-dominant, but CYP3A4 and CYP2C19-driven demethylation produces N-desmethylclomipramine, a NET-preferring secondary amine, so at steady state you get dual monoaminergic coverage without deliberately engineering it. Thats a legitimately non-trivial pharmacokinetic story.

But none of that is new. The SERT mechanism was worked out decades ago. The OCD indication is mature to the point where the main clinical question is how it compares to SSRIs in treatment-resistant cases, and that question has been asked and partially answered many times over. The off-target burden, muscarinic block, H1 antagonism, alpha-1 and sodium channel activity, makes clomipramine a dirty probe for anything requiring clean SERT signal. If you need a SERT-selective tool in a model system, you’re reaching for citalopram or escitalopram, not this.

Where clomipramine still earns real bench value is as a reference standard in OCD neurobiology. The serotonin hypothesis of OCD is actually more complex than it sounds: there’s ongoing work around 5-HT2A contributions, orbitofrontal circuit modulation, and the genuinely unresolved question of why SERT saturation matters more in OCD than in other anxiety-adjacent disorders. Clomipramine is the clinical anchor for those comparisons. We also think the cataplexy research angle is underappreciated; it remains one of the few compounds with both mechanistic plausibility and real clinical signal in narcolepsy-associated cataplexy, and that’s a small but legitimate research context.

Honestly, the evidence quality here is as high as it gets. Decades of RCTs, multi-site replication, clear regulatory validation. But thats almost the problem: when evidence is this mature, the interesting questions are mostly downstream of the compound, not about it. What we don’t like about recommending this as a primary research focus is that a bench investigator picking it up today is almost certainly asking a comparative or clinical question, not a mechanism-frontier question. That makes it a solid reference tool and a useful historical benchmark. It’s not where serious research resources go to find new answers.

Novelty

20

Mechanism promise

25

In-category differentiation

45

Evidence quality

75

Translational signal

70

Research bench value

55

Rationale Clomipramine scores high on evidence quality and translational signal (FDA-approved, decades of replicated OCD RCTs, reference-standard status) but low novelty and mechanism scores drag the overall down hard; the SERT story is fully mature and the off-target burden makes it a poor clean probe for mechanism work despite its unique clinical niche.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (chlorinated tertiary amine)

A chloro-substituted TCA with the most potent SERT inhibition in the class; the only TCA with FDA approval for OCD.

Abstract

Clomipramine (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 303-49-1; molecular formula C19H23ClN2; molecular weight 314.85) is a 3-chloro-substituted analog of imipramine developed at Geigy and approved by the FDA in 1989 under the trade name Anafranil. The chloro substitution shifts transporter selectivity sharply toward SERT (SERT Ki approximately 0.28 nM, the most potent in the TCA class; NET Ki approximately 38 nM). The active metabolite N-desmethylclomipramine (formed via CYP3A4/CYP2C19) is a NET-preferring secondary amine, producing balanced steady-state monoaminergic activity from a SERT-dominant parent. Off-target activity parallels other tertiary amine TCAs: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 19 to 37 hours. The compound is the only TCA with FDA approval for obsessive-compulsive disorder, an indication where the SSRI class typically requires higher doses; clomipramine remains a benchmark in treatment-resistant OCD. Used as the reference SERT-potent TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-220Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Brexpiprazole

Plain-language summaryIntrigue 62 / 100

Brexpiprazole (Rexulti) is Otsuka’s refined successor to aripiprazole, approved in 2015. The key tuning is lower intrinsic activity at the dopamine D2 receptor (about 14 percent rather than aripiprazole’s 30 percent), which translates to less akathisia (motor restlessness), the side effect that drove many patients off aripiprazole. The receptor occupancy profile is otherwise broadly similar. Brexpiprazole has FDA approval for schizophrenia, as add-on to antidepressants for major depressive disorder, and notably became the first drug specifically approved for agitation associated with Alzheimer dementia in 2023. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Mature D2 partial agonist; a solid reference compound for intrinsic activity research, not a frontier target

Look, brexpiprazole is what happens when a well-understood mechanism gets refined rather than replaced. Otsuka took aripiprazole’s D2 partial agonist chassis and tuned the intrinsic activity down from about 30 percent to 14 percent. That’s real pharmacology. The result is reduced akathisia and a cleaner receptor profile, making it useful as a reference compound for separating out the consequences of D2 intrinsic activity from the other variables that shift across the atypical antipsychotic class. But from a research novelty standpoint, this conversation was largely over by the time Rexulti got FDA approval in 2015.

The mechanism profile is multi-target in the right ways: D2 partial agonism at Ki around 0.30 nM, 5-HT1A partial agonism at Ki around 0.12 nM, and 5-HT2A antagonism. Thats the third-generation antipsychotic formula that aripiprazole pioneered. Brexpiprazole doesn’t change the formula so much as optimize one parameter. For bench work probing the consequences of D2 intrinsic activity levels, it has genuine utility. Pair it with aripiprazole and cariprazine and you get a gradient of intrinsic activities to work across. That’s the legitimate research angle.

What’s actually interesting is the 2023 Alzheimer-associated agitation approval from the RAISE trial. In low-dopaminergic-tone patients, you want a partial agonist that doesn’t overshoot, and the low intrinsic activity specifically addresses that. The FDA approval validated the mechanism logic in a population where these distinctions really matter. We think that’s the most scientifically underappreciated part of the brexpiprazole story.

Evidence quality is solid. Multiple Phase 3 RCTs across schizophrenia, MDD adjunctive, and Alzheimer agitation give it a clinical database that most compounds in this library can’t claim. Translational signal is strong by antipsychotic standards. The problem is that a bench scientist looking for a novel target is going to find brexpiprazole thoroughly characterized. Pharmacokinetics are mapped (91-hour half-life, CYP3A4/2D6 metabolism). Receptor binding is quantified across labs. There’s not much terra incognita left.

Honestly, this is a compound that earns its library place as a reference tool and a case study in intrinsic activity pharmacology, not as a frontier target. We dont score it high because it isn’t asking a new question. It’s answering an old one very well. If your program needs a D2 partial agonist probe with low intrinsic activity and FDA-grade clinical data behind the mechanism, brexpiprazole is the right compound. If you’re hunting the frontier, look elsewhere.

Novelty

22

Mechanism promise

42

In-category differentiation

35

Evidence quality

75

Translational signal

65

Research bench value

38

Rationale Brexpiprazole is a 2015-approved incremental refinement of aripiprazole’s well-established D2 partial agonist mechanism, scoring low on novelty and differentiation but high on evidence quality and translational signal. Its primary research value is as a reference probe for intrinsic activity comparisons and, more recently, as a case study in how low D2 intrinsic activity performs in low-dopaminergic-tone populations following the 2023 Alzheimer agitation approval.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

D2 partial agonist atypical antipsychotic

A second-generation D2 partial agonist refined from aripiprazole; lower D2 intrinsic activity producing reduced akathisia.

Abstract

Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; CAS 913611-97-9; molecular formula C25H27N3O2S; molecular weight 433.57) is a D2 partial agonist developed at Otsuka as a successor to aripiprazole and approved by the FDA in 2015 under the trade name Rexulti. The structural change from aripiprazole replaces the 2,3-dichlorophenyl with a benzothiophen-4-yl, modulating receptor binding kinetics. D2 affinity (Ki approximately 0.30 nM) is comparable to aripiprazole, but intrinsic activity is lower (approximately 14 percent versus 30 percent), producing reduced akathisia and less D2 receptor activation in low-dopaminergic-tone regions. 5-HT1A partial agonism (Ki approximately 0.12 nM) and 5-HT2A antagonism are retained. Plasma half-life is 91 hours; metabolism is via CYP3A4 and CYP2D6. Approved for schizophrenia, MDD adjunctive, and (2023) Alzheimer-associated agitation. Used as the reference second-generation D2 partial agonist with reduced intrinsic activity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-237Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydroxyzine

Plain-language summaryIntrigue 56 / 100

Hydroxyzine (Atarax, Vistaril) is a first-generation antihistamine from UCB, approved in 1956, that crosses the blood-brain barrier readily and produces sedation and anxiolysis as a result. It is FDA-approved for anxiety and pruritus (itching), and unlike benzodiazepines it has no dependence or withdrawal potential, which makes it a useful first-line option for situational anxiety in patients with substance use histories. The trade-off is that the same antihistamine and anticholinergic effects produce dry mouth, constipation, urinary retention, and next-day grogginess. The active leftover after liver metabolism is cetirizine (Zyrtec), the over-the-counter allergy drug, which does not cross into the brain at clinical doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1956-approved FDA drug with solid clinical evidence and essentially no research frontier left to explore

Look, hydroxyzine is a real drug. FDA approved in 1956, over a billion patient-exposures, solid randomized data for generalized anxiety and pruritus, a clean non-scheduled status that made it clinically useful before buspirone or the SSRIs arrived. We’re not dismissing it clinically. We’re saying there’s almost nothing here for a bench investigator in 2026 that hasn’t been settled for decades.

The mechanism is H1 antagonism at roughly 2 nM affinity, secondary 5-HT2A blockade around 10 nM, and a weak D2 component. That multi-receptor fingerprint is interesting in the abstract, but it’s fully mapped, well-understood, and not pointing at anything new. The 5-HT2A angle doesn’t give you psychoplastogen biology; the D2 component isn’t the basis for a new antipsychotic story. You’re reading 1980s receptor binding papers when you go looking for mechanism literature here.

What’s genuinely useful about hydroxyzine as a research tool is the metabolite relationship. Hydroxyzine produces cetirizine in vivo, and cetirizine loses CNS penetration because of the carboxylic acid group. That pairing has been used as a probe model to interrogate what H1-mediated CNS penetration actually contributes versus peripheral H1 blockade. Thats a narrow but real utility. If you’re building a pharmacokinetic or CNS-penetration model around first-generation antihistamines, hydroxyzine earns a seat at the table. For anything else, it doesn’t.

The evidence base is strong by the standards of research compounds. Multiple replicated RCTs across anxiety and pruritus indications, decent Hamilton Anxiety Rating Scale data, perioperative sedation trials. The HAMA studies from the 1970s through the 1990s were reasonably well-designed for their era. You’re not dealing with single-lab preclinical data and Croatian rodent models here. But strong evidence for a fully-characterized approved drug is actually the least interesting kind of strong evidence when you’re trying to identify what to study next.

We don’t see a compelling frontier angle. The anxiolysis mechanism isn’t being revisited in a new light. The H1 space isn’t generating exciting new biology. The drug’s non-controlled status is a clinical feature, not a research opportunity. If your program touches first-gen antihistamines as comparators or pharmacokinetic probes, hydroxyzine is a reasonable tool to have documented. As a primary research target in its own right, honestly, you’re working from a 1956 foundation with nowhere obvious to go.

Novelty

12

Mechanism promise

22

In-category differentiation

32

Evidence quality

68

Translational signal

65

Research bench value

45

Rationale Hydroxyzine scores low on novelty and mechanism because it’s a 70-year-old approved drug with a fully characterized H1/5-HT2A/D2 profile; the high evidence and translational scores reflect its genuine approved-drug trial base, but those can’t rescue the overall when the compound offers nothing a serious investigator hasn’t seen. Bench value gets a modest credit for its canonical probe role comparing CNS-penetrant vs. non-penetrant antihistamine effects via its cetirizine metabolite relationship.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation H1 antihistamine anxiolytic

A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

Abstract

Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-253Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
LGD-3303

Plain-language summaryIntrigue 42 / 100

LGD-3303 is a less-well-known SARM from Ligand Pharmaceuticals, developed as a candidate for osteoporosis. In ovariectomized rat models (the standard postmenopausal-bone preclinical model) it produced bone anabolic effects comparable to or exceeding raloxifene, with relatively favorable bone-versus-muscle selectivity. Phase 1 human studies were conducted but the compound did not advance further, and full clinical results were never published. It is occasionally encountered as a research chemical but is much less common than ostarine or ligandrol. Limited human data and an inactive development program limit clinical relevance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Bone-selective SARM with a stalled development record and thin independent evidence base

Look, LGD-3303 deserves a fair read before you dismiss it, but that fair read lands it pretty low on the priority list. It’s a non-steroidal SARM with a genuinely interesting tissue selectivity profile: preclinical data in ovariectomized rats showed bone anabolic activity on par with or exceeding raloxifene, while prostate-sparing effects were better than what you’d expect from a compound this anabolically active. That tissue dissociation story is the most interesting thing LGD-3303 has going for it. Most SARMs optimize for muscle. This one was explicitly engineered for bone. Thats a real, if narrow, research angle.

Here’s the thing though. Ligand ran a Phase 1 and then stopped. The compound never moved to Phase 2, and there’s no public explanation for why. That’s a ceiling, not a floor. It means the entire human-relevant evidence base is a pharmacokinetics read from a Phase 1 trial that wasn’t followed up. We’re not saying the compound failed on efficacy in humans, we’re saying we simply dont know, and the developer apparently decided the answer wasn’t worth finding out. That’s a worse position than compounds with failed Phase 2s, because at least failed Phase 2s tell you something.

The preclinical literature itself is fine but narrow. Rodent osteoporosis models are a legitimate research tool, and the OVX rat work for LGD-3303 is competent. But the independent replication is basically absent. This is a Ligand-generated compound with a Ligand-generated evidence base. The SARM class broadly has had the same problem: most of the interesting early preclinical work comes from the groups that developed the compounds. Multi-lab independent confirmation for LGD-3303 specifically is sparse.

Where we think LGD-3303 retains real, if limited, utility is as a bench-level probe for investigators studying AR conformation and tissue-selective signaling in bone biology. Its selectivity profile is genuinely distinct from RAD-140 or LGD-4033, and if your research question is about how AR agonist conformation drives tissue preference, having LGD-3303 in the panel alongside ostarine and RAD-140 gives you a data point you can’t get otherwise. The 24-hour plasma half-life is also convenient for rodent dosing protocols. That’s not nothing.

But honestly, if you’re not specifically interrogating bone-selective AR pharmacology, theres no compelling reason to put LGD-3303 on your bench over better-evidenced SARMs. The novelty is modest, the human signal is almost absent, and the development history doesn’t inspire confidence. We score it where the evidence puts it: a niche probe with a specific but narrow use case, not a compound to prioritize in a general research program.

Novelty

28

Mechanism promise

38

In-category differentiation

35

Evidence quality

28

Translational signal

22

Research bench value

38

Rationale LGD-3303 scores low primarily because Phase 1 completion without Phase 2 advancement is a genuine negative translational signal, and the evidence base is almost entirely from Ligand’s own development program. The bone-over-muscle selectivity is a real and mechanistically interesting differentiator within the SARM class, but it isn’t compelling enough to offset thin replication and a dead development program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator

A non-steroidal SARM developed by Ligand Pharmaceuticals for osteoporosis; less studied than ligandrol.

Abstract

LGD-3303 (9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one; molecular formula C16H14ClF3N2O; molecular weight 342.74) is a non-steroidal SARM developed by Ligand Pharmaceuticals as a candidate for osteoporosis. Preclinical studies in ovariectomized rats demonstrated strong bone anabolic activity comparable to or exceeding raloxifene at appropriate doses, with reduced prostate effects. Tissue selectivity profile favors bone over muscle within the SARM class. Phase 1 human studies were conducted but the compound did not advance to phase 2. The compound retains research utility for bone-focused SARM pharmacology and is occasionally used recreationally. Plasma half-life is approximately 24 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-269Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Ganirelix

Plain-language summaryIntrigue 40 / 100

Ganirelix (Antagon, Orgalutran) is the second commercial GnRH antagonist, mechanistically identical to cetrorelix and used in the same IVF protocols for the same purpose: blocking the premature LH surge. The two drugs differ in fine structure and pharmacokinetics (ganirelix has a slightly shorter half-life), but in practice clinicians choose between them based on availability, formulation preference, and cost. Same daily dosing schedule, same side effect profile, same indication. The choice between cetrorelix and ganirelix mostly does not matter clinically. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

A me-too GnRH antagonist that’s clinically proven but offers nothing over cetrorelix for research purposes

Look, ganirelix is fine. It works in the clinic. FDA approved it in 1999, it’s in IVF protocols across the world, and if you need to suppress an LH surge in a controlled ovarian stimulation context it will do exactly that. That’s not the question. The question is whether a serious investigator should care about it as a research compound in 2026, and the honest answer is almost certainly not.

The mechanism is competitive GnRH receptor antagonism. Clean, immediate, dose-dependent LH and FSH suppression. We knew this in the late 1980s when the first-generation GnRH antagonists were being developed. Ganirelix’s structural twist versus cetrorelix, the diethylhomoarginine substitutions at positions 6 and 8, was interesting at the time as a way to reduce histamine release compared to earlier antagonists. That problem has been solved. The mechanism is completely understood and has been for two decades. There is no novel pharmacology here.

The differentiation problem is even starker. Head-to-head trials against cetrorelix show comparable efficacy. The half-life is about 13 hours versus cetrorelix’s longer profile, which is an argument for daily dosing in IVF but is not a compelling research angle. If you’re studying HPG axis suppression as a research program, cetrorelix gets you to the same answer. If you need the GnRH-receptor probe specifically, both compounds serve equally well. Ganirelix doesn’t let you ask a question you couldn’t ask with the alternative; thats the bench value test it fails.

We dont want to undersell the evidence base. Phase 2 and 3 trials exist, replication across multiple clinical groups is real, the regulatory dossier is legitimate. But clinical validation of an IVF drug’s ability to prevent premature LH surges isn’t what drives research merit in 2026. The interesting HPG research questions right now involve kisspeptin signaling, GnRH pulse dynamics in metabolic disease, and novel downstream consequences of HPG suppression in non-reproductive contexts. Ganirelix doesn’t advance any of those fronts in a unique way.

What we’re left with is a well-characterized clinical workhorse that’s interchangeable with its closest competitor for essentially any research application we can imagine. The evidence quality and translational signal scores are the only things keeping this out of the low twenties. If your program specifically requires a GnRH antagonist probe and you have ganirelix on hand, it’s not useless. As a primary research target? There’s no argument to be made.

Novelty

15

Mechanism promise

22

In-category differentiation

12

Evidence quality

70

Translational signal

65

Research bench value

28

Rationale Ganirelix scores low on novelty and differentiation because the abstract explicitly states comparable clinical efficacy to cetrorelix and an identical mechanism of action; the only structural distinction (diethylhomoarginine at positions 6 and 8 vs cetrorelix’s homoarginine) produces no meaningful pharmacological differentiation that would interest a bench investigator. Evidence quality and translational signal are solid by virtue of FDA approval and IVF clinical use, but those strengths don’t compensate for the near-zero research novelty.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH antagonist

A synthetic GnRH receptor antagonist; mechanistically similar to cetrorelix and used in the same IVF protocols.

Abstract

Ganirelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-(Et)2HArg-Leu-(Et)2HArg-Pro-D-Ala-NH2; CAS 124904-93-4; molecular formula C80H113ClN18O13; molecular weight 1570.35) is a synthetic GnRH antagonist decapeptide developed at Organon and approved by the FDA in 1999 under the trade name Antagon (US) and Orgalutran (EU). Mechanism is identical to cetrorelix: competitive GnRH receptor antagonism producing immediate dose-dependent LH and FSH suppression. Structurally distinct from cetrorelix by the diethylhomoarginine residues at positions 6 and 8. Plasma half-life is approximately 13 hours after subcutaneous dosing, shorter than cetrorelix but adequate for daily IVF protocol dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF. Comparable clinical efficacy to cetrorelix in head-to-head trials. Used as an alternative GnRH antagonist in IVF and HPG suppression research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-286Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pinoline

Plain-language summaryIntrigue 40 / 100

Pinoline is a methoxylated tetrahydro-beta-carboline that the body makes endogenously, found in pineal gland and brain tissue. Biosynthetically it sits between the tryptamines (DMT, 5-MeO-DMT) and melatonin, which has fueled the long-disputed hypothesis that the pineal gland produces endogenous psychedelic compounds (the so-called DMT-pineal theory associated with Rick Strassman). Pharmacologically it is a weak reversible MAO-A inhibitor and a weak serotonin reuptake inhibitor. Concrete physiological function remains speculative, with most claims resting on tissue distribution and conjecture rather than controlled human studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Niche endogenous beta-carboline with contested pineal biology and a very thin evidence base

Pinoline sits at a genuinely interesting intersection: it’s endogenous, it comes from the pineal gland, and it’s biosynthetically adjacent to the tryptamine family in a way that gets researchers excited about what it might be doing in vivo. We get that appeal. But when you actually dig into the pharmacology and the evidence base, the picture gets much murkier.

The mechanism is dual but weak. MAO-A inhibition (reversible, low potency) plus serotonin reuptake inhibition – neither of these is novel, and at the concentrations pinoline appears at endogenously, the functional significance is genuinely unclear. The compound has been implicated in the contested endogenous psychedelic hypothesis alongside DMT and 5-MeO-DMT, but this remains exactly that: a hypothesis. There’s no clean mechanistic story that says pinoline does X in the pineal at Y concentration and this matters for anything measurable.

The evidence problem is serious. Human pharmacokinetics are sparsely documented – the monograph says so directly, and thats not a small caveat, thats the whole ballgame for translational relevance. Most of the interesting preclinical work is old, small, and poorly replicated. There’s no equivalent of the Croatia-based BPC-157 group or the Khavinson lab anchoring a body of literature here. Multi-lab replication of the more interesting mechanistic claims is essentially absent.

Translational signal is correspondingly weak. Detection in pineal and brain tissue establishes endogenous presence but doesnt establish physiological role. The gap between found it there and it does this in humans remains very wide, and there’s no serious clinical program trying to close it. Contrast this with MOTS-c or SS-31, where the endogenous origin story is paired with a defined mitochondrial mechanism and real phase 2 data.

What pinoline has going for it is narrow but real probe value. If your lab is working on endogenous beta-carboline chemistry, MAO-A biology in a tryptaminergic context, or the broader contested field of pineal-derived signaling, pinoline is a useful reference compound. The biosynthetic relationship to melatonin and the structural adjacency to N,N-DMT give it genuine interest as a tool for mapping that chemical space. Thats a legitimate use case.

Honestly, the compound scores where it scores because the research space it occupies is real but small, the evidence is thin, the mechanism is not particularly elegant, and the translational gap is wide. For a lab specifically investigating beta-carboline pharmacology or endogenous pineal chemistry, it earns a place on the shelf. For anyone else, there are higher-signal targets in almost every adjacent category.

Novelty

40

Mechanism promise

32

In-category differentiation

40

Evidence quality

22

Translational signal

18

Research bench value

40

Rationale Weak dual MAO-A/SRI mechanism with low endogenous concentrations and unclear physiological role; evidence is sparse and poorly replicated, limiting scores heavily on evidence quality and translational signal; bench value is real but narrow, confined to labs specifically investigating beta-carboline or pineal-derived signaling chemistry.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous beta-carboline (6-methoxy-tetrahydro-beta-carboline)

An endogenous methoxylated tetrahydro-beta-carboline; a methylated tryptamine derivative implicated in pineal gland function.

Abstract

Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline, 6-MeO-THBC; CAS 20684-89-1; molecular formula C12H14N2O; molecular weight 202.25) is an endogenous beta-carboline alkaloid identified in pineal gland and brain tissue. The compound is biosynthetically related to melatonin and to the tryptamines (DMT, 5-MeO-DMT) and is hypothesized to participate in endogenous psychoactivity (the contested DMT-pineal hypothesis). Pharmacologically, pinoline is a weak reversible MAO-A inhibitor and a serotonin reuptake inhibitor; the in vivo concentrations are low and its physiological role is incompletely characterized. Plasma half-life and pharmacokinetics in humans are sparsely documented. Used as a research probe for endogenous beta-carboline chemistry and pineal-gland-derived signaling.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-336Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Naloxone

Plain-language summaryIntrigue 64 / 100

Naloxone, sold as Narcan, is the standard reversal agent for opioid overdose. It competitively binds and displaces opioids from the mu-opioid receptor with high affinity, restoring breathing within minutes when administered intramuscularly or as an intranasal spray. Public health programs have made intranasal naloxone available without prescription in pharmacies and from harm-reduction organizations across most of the US, and bystander administration is credited with thousands of overdose reversals annually. The short half-life means re-dosing may be required for long-acting opioids like methadone or fentanyl analogs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

50/100

The canonical opioid antagonist probe; indispensable in its niche but far from a novel research target

Look, naloxone isnt a research target. It’s a research tool. That distinction matters a lot when you’re trying to explain a score of 50, which might seem high for a compound that scores 12 on novelty and 22 on mechanism promise. The thing is, those two axes tell the truth about where naloxone sits right now: it’s a 1971 FDA approval with a completely understood competitive antagonism profile at mu-opioid receptors (Ki approximately 1 nM), and nobody in the field is surprised by any of that. The pharmacology is textbook. The mechanism is single-receptor competitive antagonism, about as mechanistically unexciting as it gets for a research library context.

So why does it score 50 at all? Because evidence quality and translational signal are very real, and bench value is genuinely high. As the canonical short-acting, reversible mu-opioid antagonist, naloxone is what you reach for when you want to attribute an effect to opioid receptor activation. You can’t do serious opioid pharmacology without it. In animal behavioral models, in ex vivo receptor binding, in cell culture signaling studies, naloxone is the probe that closes the loop. There’s a reason every paper on endogenous opioids, opioid-mediated analgesia, or itch involves a naloxone blockade condition. It’s not doing anything exciting on its own; it’s the negative control that makes everything else interpretable.

The evidence base is essentially unimpeachable. FDA approved since 1971. Decades of replicated clinical data on reversal efficacy. The intranasal 4 mg formulation has generated real public health outcome data, and the overdose reversal pharmacokinetics are thoroughly characterized across parenteral and mucosal routes. You’re not going to find an evidence-quality problem here. Translational signal similarly scores high because the clinical effect is binary and unambiguous. That’s about as clean a human signal as this field produces.

What we don’t love is the novelty situation. There’s essentially no fresh angle here for a general-purpose research program. Some investigators are poking at ultra-low-dose naloxone in paradoxical opioid sensitization models, and the toll-like receptor 4 story (the non-stereoselective TLR4 binding that the (+)-naloxone isomer isolates) is genuinely interesting mechanistic territory, but that angle hasnt produced clinical traction and remains a niche debate. The low-dose naltrexone literature is adjacent but uses a different compound with a different half-life and a different evidence trajectory.

We think naloxone belongs in the library as a reference compound: the thing you want well-documented and accessible for any research program that touches opioid receptor modulation. Its score reflects exactly what it is, high value in a specific and narrow research context, low value as a forward-looking research target. The 50 is earned by half the formula, and the other half is where it tells on itself.

Novelty

12

Mechanism promise

22

In-category differentiation

52

Evidence quality

88

Translational signal

85

Research bench value

72

Rationale Naloxone earns its 50 from very high evidence quality and translational signal as a 55-year FDA-approved clinical compound, offset by essentially zero novelty and unremarkable single-receptor mechanism; its library value is as the reference mu-antagonist probe for opioid receptor pharmacology, not as a forward-looking research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid antagonist (short-acting)

A short-acting mu-opioid antagonist; the standard reversal agent for opioid overdose.

Abstract

Naloxone ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; CAS 465-65-6; molecular formula C19H21NO4; molecular weight 327.37) is a short-acting mu-opioid antagonist approved by the FDA in 1971 (Narcan). The compound is a competitive antagonist at mu, kappa, and delta opioid receptors with preferential mu affinity (Ki approximately 1 nM). Unlike naltrexone, oral bioavailability is poor (less than 5 percent), restricting use to parenteral or intranasal administration. Plasma half-life is approximately 1 to 2 hours, shorter than most opioid agonists, requiring multiple doses or infusion in opioid overdose reversal where the half-life of the offending opioid exceeds naloxone’s. The intranasal formulation (Narcan nasal spray, 4 mg) is widely available and has driven the modern public health response to the opioid overdose epidemic. Approved indications: opioid overdose reversal, postoperative opioid reversal, opioid-induced constipation (IV form alvimopan, methylnaltrexone for that latter). Used as the canonical mu-opioid antagonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-352Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Romosozumab

Plain-language summaryIntrigue 72 / 100

Romosozumab, sold as Evenity, is a humanized antibody against sclerostin, a protein that osteocytes (bone cells embedded in mature bone) secrete to put a brake on the Wnt signaling pathway that promotes osteoblast bone formation. By neutralizing sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual-action mechanism unique among osteoporosis drugs. FDA-approved in 2019 for postmenopausal osteoporosis, it produces large bone density gains in twelve months. The label carries a black box warning for cardiovascular events based on a signal in the comparison-to-alendronate ARCH trial. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

69/100

Dual-action bone anabolic with solid phase 3 data; canonical anti-sclerostin research probe

Look, the sclerostin story is one of the more genuinely interesting pieces of bone biology to emerge in the last twenty years. Sclerostin, encoded by the SOST gene and secreted primarily by osteocytes, suppresses Wnt/beta-catenin signaling in osteoblasts. When you knock out SOST in mice you get dramatically increased bone density. Romosozumab is the pharmacological expression of that finding: a humanized IgG2 antibody that neutralizes sclerostin and, as a result, simultaneously de-inhibits bone formation and reduces osteoclast activity. That dual-action profile is genuinely unusual. Most osteoporosis pharmacology is either anabolic (teriparatide, abaloparatide) or anti-resorptive (bisphosphonates, denosumab). Romosozumab does both through a single molecular target, which is mechanistically elegant in a way the field hadn’t seen before this compound.

The evidence base is solid. The FRAME trial established safety and early efficacy against placebo; the ARCH trial went further, comparing romosozumab head-to-head against alendronate over a sequential 24-month period. ARCH showed superior vertebral, hip, and nonvertebral fracture reduction. That’s a meaningful clinical result, not a biomarker endpoint. FDA approved in 2019, black-box warning included for cardiovascular risk: in ARCH, there were more serious cardiovascular adverse events in the romosozumab arm versus alendronate. The CV signal is real and shapes research design as much as clinical practice, particularly if you’re running longer-duration bone turnover studies in cardiovascular-risk populations.

For bench-scale investigators, romosozumab is most useful as the canonical reference tool for the anti-sclerostin axis. If you’re studying Wnt pathway regulation in bone, osteocyte-osteoblast crosstalk, or sequential anabolic-to-antiresorptive strategies, this is the probe you reach for to isolate what sclerostin inhibition specifically contributes. There’s genuine ongoing mechanistic work around P1NP and CTX kinetics during the anabolic window before formation signal attenuates, and romosozumab is the defining tool for that question. No other approved compound occupies this niche.

What we dont love: the 12-month treatment ceiling (loss of efficacy with continued dosing) is a biological puzzle thats not fully resolved, and the CV safety signal creates uncertainty that constrains some long-term experimental designs. It’s also a large biological at approximately 145 kDa; sourcing research-grade material at a price that makes routine mechanistic bench work practical isn’t trivial compared to small-molecule alternatives in adjacent research areas. The overall picture is a well-validated approved biologic with genuinely interesting dual-action biology and a clear role as the defining anti-sclerostin tool. The mechanism was novel when it emerged; the biology it probes remains active. Not frontier anymore, but far from boring.

Novelty

50

Mechanism promise

75

In-category differentiation

72

Evidence quality

80

Translational signal

75

Research bench value

62

Rationale Romosozumab scores well on mechanism (dual anabolic/anti-resorptive via Wnt de-inhibition), differentiation (sole approved anti-sclerostin agent, defines its class), and evidence (FDA-approved 2019, ARCH and FRAME trials), but novelty is tempered by six years of post-approval literature and a now well-characterized Wnt/sclerostin axis. No hard cap applies; the overall lands in established-active territory where strong clinical validation meets a mechanistically interesting but no longer frontier biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Anti-sclerostin monoclonal antibody

A humanized monoclonal antibody against sclerostin; a dual-action bone agent that increases formation and decreases resorption.

Abstract

Romosozumab (CAS 909395-70-6; humanized IgG2 monoclonal antibody against sclerostin; molecular weight approximately 145 kDa) is a humanized monoclonal antibody developed by Amgen and UCB and approved by the FDA in 2019 (Evenity). The compound binds sclerostin (a glycoprotein produced by osteocytes that inhibits Wnt signaling on osteoblasts), neutralizing its inhibitory effect on bone formation. Mechanism is dual-action: increased bone formation (Wnt pathway de-inhibition on osteoblasts) plus decreased bone resorption (reduced osteoclast differentiation), an unusual combination producing more rapid BMD gains than any other osteoporosis agent. Approved for postmenopausal osteoporosis at high fracture risk. The ARCH trial demonstrated superior fracture reduction versus alendronate. Cardiovascular safety signal (increased cardiovascular events versus alendronate in ARCH) led to a black-box warning; the compound is contraindicated in patients with recent myocardial infarction or stroke. Treatment duration is 12 months (loss of effect with longer treatment). Used as the canonical anti-sclerostin agent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-368Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 53 54 55 56 57 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.